FSD Pharma and SciCann Therapeutics to Attend the CannX International Medical Cannabis Convention in Tel Aviv Israel
October 15 2018 - 5:58AM
InvestorsHub NewsWire
FSD Pharma and SciCann Therapeutics to
Attend the CannX International Medical Cannabis Convention in Tel
Aviv Israel
CSE:
HUGE
OTCQB:
FSDDF
FRA:
0K9
Toronto, ON -- October 14, 2018 --
InvestorsHub NewsWire -- FSD Pharma Inc. (“FSD
Pharma”) (CSE:
HUGE) (OTCQB:
FSDDF) (FRA: 0K9) is pleased to announce that its Head of
Scientific Advisory Board, Dr. Zohar Koren, will attend the 3rd
International Medical Cannabis Conference, (“CannX”) in Tel Aviv,
Israel from October 14 to 16,
2018.
The
CannX convention is a central annual meeting point of global
leaders in all areas related to medical cannabis and cannabinoid
medicine. The convention will feature the latest scientific
developments in this rapidly evolving field, including cultivation,
extraction and manufacturing cutting-edge technologies and clinical
research breakthroughs. The convention will also showcase Key
Opinion Leaders that are physicians and researchers including
Professor Rafael Mechoulam, the Israeli scientist who was the first
to discover the human endocannabinoid
system.
FSD
Pharma and its strategic R&D partner, SciCann Therapeutics Inc.
(“SciCann Therapeutics”), are actively seeking
novel technologies that may synergize with their own advanced
cannabinoid scientific research programs. Dr. Zohar Koren, Head of
the Scientific Advisory Board for FSD Pharma and CEO of SciCann
Therapeutics, will lead these efforts and will meet leading Israeli
scientists, clinicians, and biotech firms that wish to collaborate
with the two
companies.
Zeeshan Saeed, EVP and
Director of FSD Pharma, stated “We are excited about the attendance
of FSD Pharma at the international CannX conference through our
Head of the Scientific Advisory Board, Dr. Zohar Koren. Our deep
collaboration with SciCann Therapeutics allows us a first line look
into the heart of the thriving Cannabis R&D medical research
arena of Israel, where most advancements in cannabinoid science
have been made in the last few decades. We look forward to meeting
the leading cannabis researchers and clinicians working diligently
in Israel, and expect to review multiple collaboration
opportunities through our attendance at
CannX.”
About FSD Pharma (CSE:
HUGE) (OTCQB:
FSDDF) (FRA: 0K9)
FSD
Pharma through its wholly-owned subsidiary FV Pharma, is a licensed
producer of marijuana under the Access to Cannabis for Medical
Purposes Regulations (ACMPR) having received its cultivation
license on October 13, 2017. Headquartered at the former Kraft
plant in Cobourg, Ontario, approximately an hour's drive from
Toronto, FV Pharma management's mission is to transform the
facility into the largest hydroponic indoor cannabis facility in
the world. FV Pharma intends to target all legal aspects of the
cannabis industry, including cultivation, processing,
manufacturing, extracts and research and
development.
About SciCann
Therapeutics
SciCann Therapeutics is a Canadian-Israeli
specialty pharmaceutical company, dedicated to the development and
commercialization of novel and disruptive pharmaceutical products
that target and modulate the endocannabinoid system. SciCann
Therapeutics is active in the fields of oncology, pain management,
neurodegenerative diseases and inflammatory disorders, and develops
a line of proprietary products for the treatment of chosen life-
threatening conditions that present a high level of unmet
need.
SciCann has created a network of
collaborations with leading academic centers and medical
institutions in Israel in order to engage in cutting edge science
and rigorous clinical studies to develop its products, while using
the permissive regulatory climate in Israel for performing its
R&D programs quickly and
efficiently.
Forward-Looking
Information
Certain statements contained in this press
release constitute forward-looking information. These statements
relate to future events or future performance. The use of any of
the words "could", "intend", "expect", "believe", "will",
"projected", "estimated" and similar expressions and statements
relating to matters that are not historical facts are intended to
identify forward-looking information and are based on the
Corporation's current belief or assumptions as to the outcome and
timing of such future events. Actual future results may differ
materially. In particular, this release contains forward-looking
information relating to the development of the Corporation's indoor
cannabis facility and its business goals and objectives. The
forward-looking information contained in this press release is made
as of the date hereof, and the Corporation is not obligated to
update or revise any forward-looking information, whether as a
result of new information, future events or otherwise, except as
required by applicable securities laws. Because of the risks,
uncertainties and assumptions contained herein, investors should
not place undue reliance on forward looking-information. The
foregoing statements expressly qualify any forward-looking
information contained
herein.
ADDITIONAL
INFORMATION:
ON BEHALF OF FSD PHARMA:
Thomas Fairfull,
President and Chief Executive Officer
Email: thomas.fairfull@fvpharma.com
Telephone: (905)
686-7079
ON BEHALF OF SCICANN:
Dr. Zohar Koren,
Chief Executive
Officer
Email: zohardev@gmail.com
Cell:
+972-52-733-1424
Neither the Canadian Securities Exchange
nor its regulation services provider accept responsibility for the
adequacy or accuracy of this
release.
SOURCE FSD Pharma
Inc.
FSD Pharma (CSE:HUGE)
Historical Stock Chart
From Nov 2024 to Dec 2024
FSD Pharma (CSE:HUGE)
Historical Stock Chart
From Dec 2023 to Dec 2024